Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Tofacitinib Shows Early Potential for Treating Dermatomyositis

Carina Stanton  |  January 16, 2019

A proof-of-concept study including 10 patients treated for dermatomyositis with tofacitinib, an FDA-approved drug for RA and psoriatic arthritis, shows strong clinical efficacy…

Medicare Changes Could Have Some Patients Paying More for Drugs

Lisa Rapaport  |  January 15, 2019

(Reuters Health)—A proposed shift in Medicare coverage for medicines administered by doctors may help reduce total drug spending, but a new study suggests it may also lead to higher out-of-pocket costs for some patients. Right now, drugs given by infusion or injection in outpatient settings are covered by Medicare Part B, which is part of…

Updated ACP Ethics Manual Provides 6-Step Approach to Dilemmas

Will Boggs, MD  |  January 15, 2019

NEW YORK (Reuters Health)—The 2019 edition of the American College of Physicians (ACP) ethics manual provides a six-step approach to resolving ethical dilemmas and adds or expands sections that address emerging issues in 21st century medicine.1 “The Manual provides succinct guidance on issues that affect the patient-physician relationship, and also issues that have to do…

U.S. Lawmaker Launches Investigation into Pharma Drug Pricing

Yasmeen Abutaleb  |  January 15, 2019

WASHINGTON (Reuters)—A top U.S. lawmaker has launched an investigation into pharmaceutical industry pricing practices, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Rep. Elijah Cummings (D-Md.), who chairs the U.S. House Oversight Committee, sent letters to 12 drug makers seeking information on price increases, investment in research…

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

Michele B. Kaufman, PharmD, BCGP  |  January 14, 2019

In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab…

Intensive Patient Education May Not Be Helpful for Acute Low Back Pain

Lara C. Pullen, PhD  |  January 14, 2019

Education with recommended first-line care may not improve pain outcomes in patients with acute low back pain. When comparing patients who received education with those who received professional consultation without information or advice, researchers found patient education was no more effective than placebo at reducing depression or incidence of chronic low back pain…

Sen. Sanders, Rep. Cummings to Introduce Bill to Lower U.S. Drug Prices

Yasmeen Abutaleb  |  January 11, 2019

WASHINGTON (Reuters)—U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers. Democrats have been critical of efforts by the Trump administration to bring down drug prices after President Donald Trump promised to do so during his campaign and since being…

New York City Launches $100 Million Universal Health Insurance Program

Gina Cherelus  |  January 10, 2019

NEW YORK (Reuters)—New York City has launched a $100 million health insurance program to cover 600,000 uninsured residents, including those unable to afford coverage and those living in the United States illegally, Mayor Bill de Blasio said on Tuesday. De Blasio, now in his second term as mayor of the country’s most populous city, has…

Former Insys CEO Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  January 10, 2019

BOSTON (Reuters)—The former chief executive of Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a nationwide scheme to bribe doctors to prescribe an addictive opioid medication and has agreed to become a government witness. Michael Babich, who resigned as the Arizona-based drugmaker’s CEO in 2015, pleaded guilty in federal court in Boston to…

A Step Further: Results from the 1st ACR/ARHP Annual Meeting Walking Challenge

Carina Stanton  |  January 8, 2019

With more than 152,000 taken steps in four days, top honors in the first-ever ACR/ARHP Annual Meeting Walking Challenge go to Mark Phelan, MD…

  • « Previous Page
  • 1
  • …
  • 288
  • 289
  • 290
  • 291
  • 292
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences